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examinations of postprocedural change of BW with cor-
relation to Hct may help to clarify this issue.
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Reply from the Authors
We read with interest the letter from Lai et al [1], and
we thank them for their interest in our study [2]. The
authors raise the question that the association between
contrast-induced nephropathy (CIN) and drop in hema-
tocrit after percutaneous coronary intervention found
in our study might be explained by a greater extent of
hemodilution and, consequently, lower hematocrit in pa-
tients with CIN. While accepting this point of view as a
plausible explanation of our finding, we consider that this
does not deny the role of procedure-related blood loss in
the genesis of CIN. Lai et al reasonably state that, based
on the described calculations, the blood loss should be as
much as 510 mL to cause the observed change in hema-
tocrit level. Though the accurate amount of blood loss
cannot be assessed retrospectively, a higher drop in hema-
tocrit in our study was associated with significantly higher
rates of hemorrhagic complications and blood product
transfusion (data not published), supporting the role of
blood loss in the genesis of CIN (see Table 1).
As we mention in the Discussion section of the
manuscript, a more significant drop in hematocrit may
also be attributed to the higher incidence of periproce-
dural hypotension (due to bleeding and/or hemodynamic
instability), and to subsequent hemodilution following
more intensive fluid replacement therapy. We certainly
support the idea of periprocedural monitoring of body
weight in patients undergoing contrast medium exposure;
this should be part of the comprehensive approach to elu-
cidate the relation between drop in hematocrit and CIN,
Table 1. Incidence of access site hematoma and blood transfusion in
relation to drop in hematocrit
Quintiles of drop in hematocrit %
>2.2 to >3.9 to >5.4 to P
≤2.2 ≤3.9 ≤5.4 ≤7.4 >7.4 value
Hematoma % 4.1 4.6 5.4 7.3 23.0 ≤0.0001
Transfusion % 1.3 1.3 2.4 2.5 17.7 ≤0.0001
along with data on periprocedural hemodynamics, hydra-
tion volume, and urine output.
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PAI-1 in diabetic nephropathy
To the Editor: The mechanisms by which plasminogen
activator inhibitor-1 (PAI-1), the main plasminogen acti-
vator inhibitor, promotes fibrosis in a number of exper-
imental models, are still intensely debated. On the one
hand, PAI-1 is supposed to inhibit extracellular matrix
degradation by preventing plasmin formation. On the
other hand, it has been shown to prevent transforming
growth factor (TGF) beta activation and, thus, to pre-
vent extracellular matrix production [1]. Nicholas et al
recently provided experimental, in vivo data suggesting
that PAI-1 deficiency might be helpful in the prevention
of diabetic nephropathy: when compared to wild-type an-
imals, PAI-1 knockout mice have, thus, a lower urinary
albumin excretion and a lower synthesis of fibronectin
in the kidney after streptozotocin injection [2]. Interest-
ingly, PAI-1 is reported by these authors to enhance TGF
beta synthesis by mesangial cells, a finding that is some-
what provocative because TGF beta is itself a potent en-
hancer of the PAI-1 promoter gene, and because recent
works by Luttun et al and our group demonstrated that
PAI-1 plays a critical role in the regulation of the TGF
beta activation (i.e., PAI-1 inhibits TGF-beta activation)
[3, 4]. Moreover, in Nicholas’ study, the induction of TGF-
beta synthesis, at the mRNA and at the protein level, in
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diabetic PAI-1 +/+ mice, is weak when compared with
nondiabetic mice (×1.5), and is hardly distinguishable
from the induction observed in PAI-1 −/− mice, at least
for the eye (Fig. 3). Another striking result is that the
level of TGF-beta expression and production by the kid-
ney is higher in PAI-1 −/− mice than in PAI-1 +/+ mice,
in either basal or diabetic conditions. In the absence of
pathologic data, including measurements of the glomeru-
lar basement membrane thickness, it is therefore difficult
to conclude that PAI-1 knockout animals could be pro-
tected towards diabetic nephropathy and that this would
be related to a lower concentration of TGF-beta.
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Reply from the Authors
As we gain further insight into PAI-1–mediated mech-
anisms in disease, it is evident that PAI-1 may indeed
have several functions. Early studies showed that PAI-1
deficiency protects against fibrosis, as in the bleomycin-
induced pulmonary model [1], and this is supported by
our studies in the streptozotocin-induced diabetic mouse
model [2].
However, Hertig and Rondeau demonstrate that in in-
flammatory models of disease, PAI-1 deficiency may pro-
mote pathology. In fact, we have observed development
of cardiac fibrosis in PAI-1−/− mice (unpublished data),
as have Moriwaki et al [3], who also showed significant
macrophage involvement in this process. These observa-
tions strongly suggest that PAI-1 function may be deter-
mined by the inciting process, and modulated by uPA
expression, which may be tissue- or disease-specific.
The comment that induction of TGF-b synthesis is
weak (1.5 ×’s) reflects similar changes in total TGF-b
by Hertig et al (1.9 ×’s) [4]. Active TGF-b was not mea-
sured in our paper. As such, it is provocative to assume
that a seemingly “weak” stimulation of TGF-b protein
by PAI-1 may not have a significant clinical outcome (i.e.,
worsened albuminuria). Our data showed no significant
difference in basal kidney TGF-b expression, which was
significantly reduced in diabetic PAI-1−/− mice (Fig. 3).
Significant structural changes of diabetic nephropathy,
such as glomerular basement membrane thickness and
fractional mesangial volume, are not typically observed
after 4 weeks of diabetes in C57BL6 STZ-induced dia-
betic mice and, in fact, may not appear until ∼6 months
of diabetes. For this reason, these parameters were not
included in our study.
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Does fluvastatin really have an
antioxidant effect in humans?
To the Editor: In the recent issue of Kidney Interna-
tional, Pat et al demonstrated that renal fibrosis after
unilateral ureteral obstruction in rat was attenuated by
the antioxidative effect of fluvastatin [1], a HMG-CoA
reductase inhibitor notable for its additional antioxidant
effect [2]. We undertook this clinical experiment because
no in vivo human data are available addressing the antiox-
idant effect of fluvastatin. The patients studied consisted
of 3 males and 3 females, with an average age of 56.5
years. All had biopsy-proven chronic glomerulonephri-
tis with normal ranges of creatinine clearance and serum
total protein. The mean urinary protein excretion was
